GNCA - Earnings call transcript Q1 2020 | Genocea Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen. And welcome to the Genocea First Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.

to of conference LifeSci like host to now Ferry, Dan Advisors. would turn over the your I

Dan Ferry

Thank you, topics Operator, at we discuss issued and This genocea.com, good morning, press today. tab. that everyone. under release the outlines is the release we Investors to a plan available Earlier today,

President call prepared for Genocea's, the today, to and the Officer, provide Chip; Diantha will and CEO, review a we remarks, company's Flechtner, brief Davis, up will During the questions. Scientific available and Q&A, the Diantha; Tom then Financial call Chief Jessica corporate results. Chief the open After answer financial Chip Clark, your be will update; and Officer; Medical Officer, Genocea's, Chief Duvall, will

everyone All call are business may this XXXX. Actual forward-looking statements provided could Litigation made Before Genocea. beyond we under that and or future the as begin, statements impact the Reform many defined forecasts relating performance, Private future Genocea's to of be the I Harbor Safe conference expected prospects future or forward-looking statements control the plans differ intended protection events Securities results remind during due include such would Act subject outcomes from to Act. to the factors Reform those by of to materially of like to

Risk reports directed Commission. and the result and other as expressly XX-K information, Genocea to the its annual filed to set future Participants disclaims report with Securities any Genocea's duty of XXXX new a are Form or updates statements, whether forth to periodic Exchange forward-looking on provide events in otherwise. Factors

call the pass to to over pleasure my Chip. now It's

Chip Clark

today. you all Thanks Dan. thank joining for us And

GEN-XXX, clinical and track Genocea differentiated two our cell our pleased on neoantigen remains stage report with therapy. I'm neoantigen, our GEN-XXX to program

Let speak about GEN-XXX. more me first

conclusion believe inhibitor of certain We B clinical these sensitive checkpoint to preliminary we quarter, reach with checkpoint pending tumors. which standard-of-care in sufficient [indiscernible]. track Phase Part QX. we X/a positive enrollment the we have in have a in to about such trial provide have Therefore, results therapy patients tests clinical continued GEN-XXX on our combination Throughout attained a enrollment efficacy. remain We with

a breadth Now, for of application neoantigens, cancer avoiding potential process targeting large T unprecedented this GEN-XXX preliminary GEN-XXX. half expansion a and manufacturing in treat believe scalable best-in-class later to the unwanted in to of quarter adoptive cell new IND T clinical peripheral or turn let of file employing We to XXXX. an therapy, drug GEN-XXX cells blood results investigational with deleterious rapidly an is me expected intend first We populations. patient relevant

On overview of an our cell new need T patient the including for evolution provide May look new generated we including therapy we'll cell the Dr. as a IND and outcomes. to data the data Tran, After current Tran Steven a Dr. with XX, who cell National Eric fellow transformational T will working a potential of TIL Dr. that, the provide Rosenberg. landscape, therapy, GEN-XXX, filing. brief symposium of Institute supporting will showing approaches with at improve in-depth therapy therapy Cancer host adoptive

in to Let landscape the speak me which all finally are broader operating. we

working doing lab We based the select mid-March. by companies, affects have caused from many loss COVID-XX disruption are the since but Like way our performing essential more of saddened home employees by pandemic. and of directly too. life functions business been All

our headway scale proud forward we research team had critical have to make to activities. continuing objectives challenges, progress. of to significant despite our on these consequence, back our look and we continue our a because As I'm

call quarter, up our opening Diantha? summaries the pass to I'm before call now financials going over this to questions. the to to Diantha from

Diantha Duvall

Thanks everyone. and Chip, good morning,

$XX.X quarter the equivalents. cash cash and with of million ended We

$X expenses were XX, period expenses compared were XXXX for our in net XXXX. period XXXX. the same compared the Our loss quarter to And million results same same period and $X.X $X.X was million in March to and XXXX. million development ended to for $XX in million as the million, General research $XX.X operating the compared for are for administrative $XX.X follows: million

We guidance be operations first resources that our sufficient of into to reaffirm support our cash the our existing quarter XXXX. will

We meaningful are and GEN-XXX that our be optimistic will clinical progress GEN-XXX with catalysts.

ability as related preclinical market could program. slowdown COVID-XX adverse we reactions global clinical business on However, to economic our our the additional the to and our We impact to continue dynamics and and continually capital. look needs a our these progress evaluate challenging market potential significant times volatility to have raise catalysts market and during

With questions. that, for let's now call open Operator? up the

Operator

Instructions] from first is Burnett question Ben Stifel. Your [Operator with

Ben Burnett

guess a enrollment likely to just expect GEN-XXX, I sufficient follow what to B, guess give study a of in with sense we're are up quick question this you of reaching on us this look? times kind able first Part I in

Chip Clark

to this Officer Yes, Medical the I'm obviously, Tom our question thanks, Chief to Ben. Davis, is turn This going question. answer to Chip,

Tom Davis

numbers looking are adequate preliminary would up assess We allow of activity with the that patients readout. to follow us that for

that have the at. vaccine of of impact all population information in And GEN-XXX in adequate three months follow-up small on we're of have those course initially least patient, about a looking it's at each of So patients. order will to

Ben Burnett

regards to this a this lymphodepletion in anticipate is you IL-X. thinking that's GEN-XXX programs. one this that the administer program. clinic, approaching guess is to just just if something And question or having - you I ask I have you this done on now and point GEN-XXX? I how Do of sort - of a I fantastic. mean, TIL that's the was do curious lot Okay, about you with follow-up do are could at

Chip Clark

is really imagine, just the but thinking questions you Yes, have answer as these this can debating, our us, are not important field that I'll question. Tom on

Tom Davis

yes, Well, is question. that great a

technology. specifically and thought of have this for of And IL-X therapies. use lymphodepletion both noted, research be to you most in on the As important the focused those TIL particular

CAR-Ts. necessary, the both IL-X not for what's field in entirely used that during not However, clear general, it's for is

been think not question answered. I has the

trial and a clinical a start be dose, out with And it's GEN-XXX low therapy. for deploying our we IL-X escalation. will not will dose So lymphodepletion

do seeing more GEN-XXX the lymphodepletion in And TIL be escalate can dose we'll cells dose what to essentially and then include does traditional high will We that type IL-X. a regimen up vivo.

with toxic to doses technology, therapy. of lower it's understand important after be would with since we'll perhaps number hope think many to we optical perhaps that with able cells, large numbers going I different cell to targets less concomitant be with generate overall, adequate a

we at So to for be product with your question our hoping answering actual data. least are

Operator

Graybosch with Your Leerink. next Daina is SVB question from

Daina Graybosch

And us enrollment I'll types, that study, indications your a before whether as with you've on the tumor questions, second two GEN-XXX halted then of in had enrolled any progressed for were answer have patient that for adding I question. you've you that sense you checkpoint my wait can give their GEN-XXX? enrolled

Chip Clark

Dana, Tom Sure, to to thanks hand the that for question. once again, answer. And I'll

Tom Davis

have of onto a know, you tumor those can we types enrolled, study five basket tumor that So as be the have study. it's put from we five and types patients each had

not. So tumor expect from checkpoint tumors, which we'll are across inhibition, be at at the would have type, day, of to of end the of least are data others some. looking some each responsive which the one more We very of to and of spectrum

possible, care have of progressed vaccinate responsive and are estimate types with we tumor patients setting disease the you that to of refractory in the imagine, recurrent might as those asked, to you the standard to do where settings. who continue less or to this in potential will As plan fully patients some GEN-XXX contain

have refractory collecting to significant those regression then patients, as inhibitors, may As there evidence certainly going data any following who patients be would well vaccination you they in exciting. do we're of of controlled know, a and also if by tumor be we be less are very do challenge, we see that certainly checkpoint But well.

Daina Graybosch

forward. second this and GEN-XXX heard and you've about investors for is versus my could theoretical what scientific explored question polyclonal And I cells. of talk why populations if cells choices cell GEN-XXX. made one the new And going Great. patient's T you've about you've made dendritic synthetic more about you asking the making own more wonder that I dendritic

Chip Clark

why if the that Is the we used versus specifically own we Dana, is choice? dendritic patient's question So made have cells question? - synthetic why and the that

Daina Graybosch

taking address I day well. in lot ultimately, a more the KOL and and Yes, as might you're GEN-XXX and you what realize upcoming forward

Chip Clark

You're absolutely the of a our in Jessica - speak speak can KOL still that can Jess ton to why. information will Flechtner done still right, think and data, have we've but CFO I what

Jess? So

Jessica Flechtner

Hi, Daina, thanks for the question.

in it's, manufacturing your that You one limiting. still the they they know, have control - especially are process. very that synthetic you in interesting But limitation, APCs can facet fill more HLA fact because are it's

I'm least aware today the You every using has can't ones allele by that the cover of. that synthetic APCs, at patient

use to process, industrialized And our have peripheral we from manufacturing presenting derive their antigen that in really our ability we cells optimized their the own and blood so process. for

Operator

Baird. the question is next Your with line Mike from of Ulz

Mike Ulz

on GEN-XXX. had Just one

data what with on to just more are of some preliminary what terms the the And you thinking a targeting quarter, guiding medical then of follow-up top of questions expect secondly, a you release? line You're particular Are a earlier D in to Part that third meeting? in data.

I on what maybe you if as more small you give the don't clarity I think that. patients know you by characterized a number can but of us Tom little Thanks. mean

Chip Clark

Mike, Tom of those questions. the take have both thanks for questions. I'll Yes,

Tom Davis

look number allow have of to and so would it. adequate Yes, we for want an to identify signal patients clearly that us

trial. the to as the heard, the data. accrual the time And complete we'll by to want process we've effectively for through present see very you've accrued have we patients being, what We halted and time

for somewhere To as initiation to in see at answer vaccination. the focus to know, be course, enough And is your expecting have some looking we're to patients XX XX question bulk going changes setting. though our after specific be here and in activity between of of tumor able least you patients, specific to

those initiation vaccine vaccination patients change true as any serving a a will contribution the after of from own using and fairly the analysis. represent each careful So should evidence itself, of control their be of

patients, that think sense do the be against number we're since get disease. altering to or historic cause we should clear be not this with comparing a going we able not significantly whether of of So we're controls, of to

we you now. As far times would unpredictable where are know, as present, somewhat

we course Sometime could is be academic separate that applied but it's appropriate meeting you there us several it heard, to could are in such an as QX, if from meetings that. could do - of timing that for present more be

not we're said, stands be to right be sharing Chip giving on we with share and the to QX. guidance you. But it would you track, to as in data specific able we're it now where So as expecting certainly with

Operator

Your Gil Needham line Blum and is the of with next from question Company.

Gil Blum

seemed technical ongoing the considering begin pandemic? on you expect guys of difficulties First still fully logistical is track Do that all, enrollment. for to it GEN-XXX any

Chip Clark

and uncertainty be surrounding It's, the with supply can ensuring for pandemic, all, will just job great ahead experience the Gil the given the we Thanks, what done, found all chain prioritized is all, but question. and are our that details the partners that our I look supply of the speaking, the has generally in cancer to have trial challenging of of that, to care confidence continues team of, of clinical second our together with and a sweating sweating say from GEN-XXX holds details. first terrific chain also that course

when's optimistic think, trial, be are, on we But now to the from guidance once guardedly for think operate clinical patient we I have and months able much that granularity provide we able to more So and chain supply there. know, initiate what's would concrete we'll done data the be so as GEN-XXX we for you I GEN-XXX.

Gil Blum

I around these you. you that. up one, guys considering financial looking And then uncertainties mean, the Thank partners markets, just days? I at another appreciate

Chip Clark

before course. market. partners Oh, at of current capital looking the in were uncertainty We the

meaning competitive and may GEN-XXX their possibility evaluate products opportunities, to presumably partnership as GEN-XXX. ATLAS not both programs, well be the continue value potential we our own partners GEN-XXX, so, platform GEN-XXX to specific as And or that for with

And so, way that story things capital is like about think the a can strategy in we issuing vital alongside we advance capital. which as new

Operator

next Pantginis of H.C. Wainwright. question Joe with is your line from the And

Joe Pantginis

direct question no and and everyone. well One the on question. And for has doing morning, any at hope GEN-XXX Thanks is on this point. impacts GEN-XXX. at Hi, the good I one one company taking everyone

even So data to just just in impact sure sure studies to the quickly continue, to certainly pause Tom make patients, talking on because wanted as any about sounds by but wanted early like making to it was XX impacted. GEN-XXX decision a cancer have studies XX decent earlier make was on you'll set I the there COVID just been enrollment have though

Chip Clark

of question. Joe, thank for and you thanks I'll you handle question. let sentiment, the for course also, the Tom.

Tom Davis

Joe. Thanks, Sure.

accrued effectively have and analysis. actively the pre good interim, analysis, previous been accrued formal for a a wonderful of this is not this course, So we interested and this on And that participating we've capturing executing well, interim in are are I sites the quite patients both in we it's although plan very have planned number. think our a patients,

on And as are you certainly any these there missing discussion impacts can multiple may there in days, be by read, of that might COVID some imagine, data as clinical completely are the you well going resist out. from trials as are the capturing the the bulk, plots final measurements, set. we're as that the focused to data core of our reading But spider be tumor

the compromises current the and we're not the we come be will with plan do picture, shortening way for So to on big of I that COVID trial, right the in because pandemic. we're along compensate able of any think because things

Joe Pantginis

during on on XX more on touched at the just about manufacturing do or know, you When a talks want and here, whether But second talk May has investor to as on briefly I'm always that XX. it. to advances you and that. sure then go? this very know, Thanks evolution key question you commercial evolved you Got beyond. appreciate it we'll well. And from that. touched ready TIL hear have or A just IL these for been, NCI look you of manufacturing it's therapies, I

fact the that I blood getting peripheral an So you believe you you're these process. have industrialized from important an is Jess, step. that mentioned

hand, commercial for, be So know, you it you process at outstanding how should are to approval, a upon I have guess, and know, overall? the to in some we look manufacturing what of steps able

Chip Clark

Yes, Joe, the thanks for question.

possible. the available an effective You're dream as in cell to an point important highlighting making of many therapy as patients

a this much XX. more is say on on But made will point think we is scalable process we now, May have design, will that We by today. provide that, what for color I

we here point that we're the think is not I substantial so innovation. And process requiring, believe,

to If of work. works could something proposed it be, the scale we obviously trial clinical wanted would that think to small if itself we immediately, go from if the that commercializable process

we'll speak couple specific case. is so why to elements the this process, a And the and of in the of weeks

Operator

are further And questions. this at there time, no

Chip Clark

joining operator, say you, and So, I to today. us then, with will you that thank for thank everyone

Operator

this conference you Ladies have and wonderful your a for Thank participation gentlemen, concludes today's and call. day.

You may all disconnect.

Genocea Biosciences (GNCAQ) 30 Apr 202020 Q1 Earnings call transcript